

March 30, 2010

To those concerned

R-Tech Ueno, Ltd.
(Code No.4573, Osaka Securities Exchange; Hercules)
Head Office: 1-1-7 Uchisaiwai-cho, Chiyoda-ku, Tokyo
Representative: Yukihiro Mashima,
Representative Director & President
Contact: Koji Nakamura, Business Management Department;
TEL: 03-(3596) 8011

Announcement of Revision in Sales Method for Rescula® Eye Drops 0.12%
in South Korea and Taiwan

R-Tech Ueno, Ltd. has revised its method for selling Rescula® Eye Drops 0.12% in South Korea and Taiwan. A summary of the new sales method is presented below.

R-Tech Ueno, Ltd. has established the goal of becoming a global pharmaceutical company specializing in the development and sale of ophthalmology and dermatology drugs from the viewpoint of physicians. One aspect of achieving this goal is the development of drugs for unmet medical needs, drugs to treat rare medical conditions (orphan drugs), and anti-aging drugs, all of which are activities backed by the Japanese government.

Rescula® Eye Drops 0.12%, the core product of R-Tech Ueno, has been distributed in South Korea and Taiwan by Astellas Pharma Inc. Under this agreement, these eye drops were sold in South Korea by Dong-A Pharmaceutical Co., Ltd. and in Taiwan by Astellas Pharma Taiwan, Inc. As this distribution agreement with Astellas Pharma has been terminated, R-Tech Ueno is now directly outsourcing the sale of Rescula® Eye Drops 0.12% to Dong-A Pharmaceutical and Astellas Pharma Taiwan. R-Tech Ueno will give these two companies direct access to its large volume of materials, data and know-how concerning these eye drops that have been gained from selling this product in Japan for many years. R-Tech Ueno believes that this approach will contribute to growth in sales of Rescula® Eye Drops 0.12% in South Korea and Taiwan.

In order to continue growing overseas as well as in Japan, R-Tech Ueno plans to strengthen ties with companies in other countries. These partner companies can serve as bases in Asia for the joint development of potential drugs now in the pipeline and for the sale of those drugs.

R-Tech Ueno believes that this change in the distributors of Rescula® Eye Drops 0.12% will not have a significant effect on results of operations.

1. Summary of contract with Dong-A Pharmaceutical
Activity: Sale of Rescula® Eye Drops 0.12% in South Korea
Validity: April 1, 2010 to March 31, 2013

2. Summary of contract with Astellas Pharma Taiwan

Activity: Rescula® Eye Drops 0.12% in Taiwan

Validity: April 1, 2010 to March 31, 2013

Profile of Dong-A Pharmaceutical

Established in 1932, Dong-A Pharmaceutical is a global organization and the largest pharmaceutical company in South Korea. The company is involved in the development and advancement of various pharmaceuticals. Since 1967, Dong-A Pharmaceutical has been South Korea's largest pharmaceutical company in terms of sales. Ethical drugs account for 57.8% of sales and over-the-counter and healthcare related drugs for 26.2%. By market sector, cardiovascular drugs are 33.4% of sales, digestive system drugs are 24.9%, neurological drugs are 9.4% and dermatology and urology drugs are 7.9%.

Company website: <http://www.donga.co.kr/>

Profile of Astellas Pharma Taiwan

Established in 1963, Astellas Pharma Taiwan has its head office in Taipei at 10-5 Min Sheng East Road, Section 3. The company develops and sells ethical drugs in Taiwan. Capital is 460 million NT dollars and the company has a workforce of 130 (as of February 28, 2009).

Company website: <http://www.astellas.com.tw/>